Re: Cutanix Dramatic Relief Lotion -Brand New Product for cea Shown to be Effective

May 22, 2002

Sorry to reply to my own message, but the attached study I mentioned did not

show up when the Email reached the group, so I'm going to try to copy and

paste as best as I can, Unfortunately now the bar graphs won't show up this

way. It really was kinda neat the way everything was shown. If you don't

want to suffer through my crappy cut and paste job, you can see the full

study (graphs and all) at the following sight: (Great it wont even turn into

a link.. lol) I guess you'll have to type that into your browser manually.

Also, it may take a minute to load, but I'd definitely recommend everyone

check it out.

http://www.bfsforum.net/cutanixdramaticrelief.doc

Cutanix " Dramcutanix dramatic relief.docatic Relief " Lotion for Problem Skin

Cutanix has finalized a proprietary lotion formulation containing 1% by

weight of our active anti-inflammatory ingredient, CX-452, (trade name

Quadrinone?). This product will be manufactured by Paramount Cosmetics,

Clifton, NJ beginning the first week in June 2002. The product will be

introduced at a dermatology conference on May 31, 2002 and marketing will

commence immediately thereafter. A picture of the bottle design and graphics

is shown below.

Cutanix has been providing samples of this product for several months to

individuals suffering from eczema and rosacea, and the anecdotal feedback

from these volunteers has been extremely positive. The product was found to

be effective in reducing the severity of the disease in all eczema

volunteers and in most rosacea individuals. Because of this marked anecdotal

success Cutanix commissioned a formal, IRB approved clinical study under the

direction of Zoe Draelos, MD in High Point, NC to assess the efficacy

of this proprietary " Dramatic Relief " lotion in treating patients with

either eczema or rosacea.

Eczema and cea Clinical Study

In the clinical research study conducted by Dr. Draelos, 20 subjects with

eczema and 20 with rosacea were treated with Cutanix " Dramatic Relief "

lotion. During their first visit, patients were evaluated by Dr. Draelos

using 4 measurements of disease: 1) erythema, 2) desquamation (peeling), 3)

uneven skin tone, and 4) dermatitis. Dr. Draelos also provided an " Overall

Severity " score which ranged from 1-6 with 6 being the most severe level of

overall disease. Patients were photographed to record the severity of the

disease. After evaluation patients were sent home with the Dramatic Relief

lotion and told to apply it morning and evening for two weeks. They then

returned to the clinic for a two-week evaluation and at that time received

more product for an additional 2 weeks. At four weeks, both Dr. Draelos and

the subjects evaluated the severity of their disease. Digital photographs of

the treated areas were also taken.

Of the 20 eczema patients treated with Dramatic Relief, 17 completed the

four-week period. None of the subjects, including those who dropped out,

experienced any irritation or other adverse effect from the product. The bar

graph below summarizes the changes in " Overall Severity " for this group at 4

weeks. As can be seen in the chart, the severity of eczema decreased in

15/17 subjects (88%). Average improvement among those responding was 67%.

This agrees with the anecdotal data Cutanix had acquired from volunteers who

used the product and is a statistically significant result.

Of the 20 rosacea patients treated with Dramatic Relief, 18 completed the

four-week period. None of the subjects, including those who dropped out,

experienced any irritation or other adverse effect from the product. The bar

graph below summarizes the changes in " Overall Severity " for this group at 4

weeks. As can be seen in the chart, the severity of rosacea decreased in

13/18 subjects (72%). Average improvement among those responding was 68%.

This agrees with the anecdotal data Cutanix had acquired from volunteers who

used the product and is a statistically significant result.

cea is a much more difficult disease to treat than eczema because of the

severity of skin inflammation and vasodilation. We were, therefore,

particularly pleased by these results. Considering that a 2% formulation of

CX-452 has been shown to be more effective in blocking UV-induced erythema

than the 1% formulation used in this clinical study, a higher strength

version of " Dramatic Relief " may provide even greater efficacy in treating

rosacea. Furthermore, Cutanix scientists have now identified several

significantly more potent compounds related in structure to CX-452, and

these may prove effective in treating the most difficult dermatological

disease, psoriasis.

www.cutanix.com

Cutanix Dramatic Relief Lotion -Brand New Product for

cea Shown to be Effective

Hey guys, I've been asked to show this to the group. Cutanix is

a small biotech-type company that is coming out with a new

product for cea. I'm not sure how well this product will

work, but it looks kinda promising. With this Email I have

attached a three page document talking about a study done with

this product on 20 cea sufferers. It only worked for

something like 72% of the people, but for those it worked for, it

reduced erythema by 67%, whereas the leading prescription drug

(Metrogel) decreased cea severity on average between 50-58%.

I've been following this company for a few months now. Originally

this product was supposed to be used to treat Seborrheic

Dermatitis. Although its role in Seb Derm is not mentioned in

this study, from what I hear, it does work really good on

Seborrheic Dermatitis, perhaps even better than it works on

Eczema or cea.

Their website is quite pathetic, but I guess they plan on

updating it soon before releasing this new product. The product

will be coming to market the first or second week in June, so,

their website should be updated by then. Because its pretty weak

at the moment, I'm not sure, but I believe this excerp is about

the product they are releasing:

" Cutanix has identified compounds from a new class of small

molecules that we believe could be effective in treating one or

more inflammatory skin diseases, such as irritant dermatitis,

allergic contact dermatitis, seborrheic dermatitis, atopic

dermatitis and psoriasis. These compounds have the ability to

block at multiple points the inflammatory cascade central to all

such diseases. They do this by attenuating one of the two key

signal transduction pathways within cells involved in cells'

inflammatory response. This pathway contains the p38 MAP kinease

and the AP-1 transcription factor. The other key pathway, which

contains the NF-kß transcription factor, does not seem to be

affected by these compounds. The fact that these compounds affect

only a portion of a cell's inflammatory response mechanism may

explain why they do not have side effects like corticosteroids

and other immunosuppressive drugs. Enough inflammatory genes are

dependent on the p38/AP-1 pathway, however, that inflammation in

tissue cannot be sustained if these genes are returned to normal

levels of expression. The inflammation winds down over several

days, much like a slow leak in a tire. "

Since the study was conducted by the company selling the product,

I wouldn't be surprised if it was partially biased.

Unfortunately, even though I believe they were originally going

to attempt to seek FDA approval for this item, it has since been

classified as a cosmetic, and therefore not under the regulation

of the FDA or something like that.. Not entirely sure. Anyway,

even with this being said, this product looks to be about as

promising as anything out there, so, you may wanna give it a try,

especially if you have a combination of cea and Seb Derm.

Sorry for makin' this so long! (I never can seem to say what I'm

trying to say without blathering on for ten pages)

Adam

May 22, 2002

Reads to me like the weakest design of all clinical studies -- no one

is blinded, no placebo comparison, no standard scale used to assess

features, and a very misleading graph presentation that

(deliberately, I'm sure) overstates its claims.

Marjorie

Marjorie Lazoff, MD

> Sorry to reply to my own message, but the attached study I

mentioned did not

> show up when the Email reached the group, so I'm going to try to

copy and

> paste as best as I can, Unfortunately now the bar graphs won't show

up this

> way. It really was kinda neat the way everything was shown. If

you don't

> want to suffer through my crappy cut and paste job, you can see the

full

> study (graphs and all) at the following sight: (Great it wont even

turn into

> a link.. lol) I guess you'll have to type that into your browser

manually.

> Also, it may take a minute to load, but I'd definitely recommend

everyone

> check it out.

> http://www.bfsforum.net/cutanixdramaticrelief.doc

>

> Cutanix " Dramcutanix dramatic relief.docatic Relief " Lotion for

Problem Skin

>

> Cutanix has finalized a proprietary lotion formulation containing

1% by

> weight of our active anti-inflammatory ingredient, CX-452, (trade

name

> Quadrinone?). This product will be manufactured by Paramount

Cosmetics,

> Clifton, NJ beginning the first week in June 2002. The product will

be

> introduced at a dermatology conference on May 31, 2002 and

marketing will

> commence immediately thereafter. A picture of the bottle design and

graphics

> is shown below.

> Cutanix has been providing samples of this product for several

months to

> individuals suffering from eczema and rosacea, and the anecdotal

feedback

> from these volunteers has been extremely positive. The product was

found to

> be effective in reducing the severity of the disease in all eczema

> volunteers and in most rosacea individuals. Because of this marked

anecdotal

> success Cutanix commissioned a formal, IRB approved clinical study

under the

> direction of Zoe Draelos, MD in High Point, NC to assess the

efficacy

> of this proprietary " Dramatic Relief " lotion in treating patients

with

> either eczema or rosacea.

>

> Eczema and cea Clinical Study

>

> In the clinical research study conducted by Dr. Draelos, 20

subjects with

> eczema and 20 with rosacea were treated with Cutanix " Dramatic

Relief "

> lotion. During their first visit, patients were evaluated by Dr.

Draelos

> using 4 measurements of disease: 1) erythema, 2) desquamation

(peeling), 3)

> uneven skin tone, and 4) dermatitis. Dr. Draelos also provided

an " Overall

> Severity " score which ranged from 1-6 with 6 being the most severe

level of

> overall disease. Patients were photographed to record the severity

of the

> disease. After evaluation patients were sent home with the Dramatic

Relief

> lotion and told to apply it morning and evening for two weeks. They

then

> returned to the clinic for a two-week evaluation and at that time

received

> more product for an additional 2 weeks. At four weeks, both Dr.

Draelos and

> the subjects evaluated the severity of their disease. Digital

photographs of

> the treated areas were also taken.

>

> Of the 20 eczema patients treated with Dramatic Relief, 17

completed the

> four-week period. None of the subjects, including those who dropped

out,

> experienced any irritation or other adverse effect from the

product. The bar

> graph below summarizes the changes in " Overall Severity " for this

group at 4

> weeks. As can be seen in the chart, the severity of eczema

decreased in

> 15/17 subjects (88%). Average improvement among those responding

was 67%.

> This agrees with the anecdotal data Cutanix had acquired from

volunteers who

> used the product and is a statistically significant result.

>

> Of the 20 rosacea patients treated with Dramatic Relief, 18

completed the

> four-week period. None of the subjects, including those who dropped

out,

> experienced any irritation or other adverse effect from the

product. The bar

> graph below summarizes the changes in " Overall Severity " for this

group at 4

> weeks. As can be seen in the chart, the severity of rosacea

decreased in

> 13/18 subjects (72%). Average improvement among those responding

was 68%.

> This agrees with the anecdotal data Cutanix had acquired from

volunteers who

> used the product and is a statistically significant result.

>

> cea is a much more difficult disease to treat than eczema

because of the

> severity of skin inflammation and vasodilation. We were, therefore,

> particularly pleased by these results. Considering that a 2%

formulation of

> CX-452 has been shown to be more effective in blocking UV-induced

erythema

> than the 1% formulation used in this clinical study, a higher

strength

> version of " Dramatic Relief " may provide even greater efficacy in

treating

> rosacea. Furthermore, Cutanix scientists have now identified several

> significantly more potent compounds related in structure to CX-452,

and

> these may prove effective in treating the most difficult

dermatological

> disease, psoriasis.

>

> www.cutanix.com

>

> Cutanix Dramatic Relief Lotion -Brand New

Product for

> cea Shown to be Effective

>

> Hey guys, I've been asked to show this to the group. Cutanix is

> a small biotech-type company that is coming out with a new

> product for cea. I'm not sure how well this product will

> work, but it looks kinda promising. With this Email I have

> attached a three page document talking about a study done with

> this product on 20 cea sufferers. It only worked for

> something like 72% of the people, but for those it worked for, it

> reduced erythema by 67%, whereas the leading prescription drug

> (Metrogel) decreased cea severity on average between 50-58%.

> I've been following this company for a few months now. Originally

> this product was supposed to be used to treat Seborrheic

> Dermatitis. Although its role in Seb Derm is not mentioned in

> this study, from what I hear, it does work really good on

> Seborrheic Dermatitis, perhaps even better than it works on

> Eczema or cea.

>

> Their website is quite pathetic, but I guess they plan on

> updating it soon before releasing this new product. The product

> will be coming to market the first or second week in June, so,

> their website should be updated by then. Because its pretty weak

> at the moment, I'm not sure, but I believe this excerp is about

> the product they are releasing:

> " Cutanix has identified compounds from a new class of small

> molecules that we believe could be effective in treating one or

> more inflammatory skin diseases, such as irritant dermatitis,

> allergic contact dermatitis, seborrheic dermatitis, atopic

> dermatitis and psoriasis. These compounds have the ability to

> block at multiple points the inflammatory cascade central to all

> such diseases. They do this by attenuating one of the two key

> signal transduction pathways within cells involved in cells'

> inflammatory response. This pathway contains the p38 MAP kinease

> and the AP-1 transcription factor. The other key pathway, which

> contains the NF-kß transcription factor, does not seem to be

> affected by these compounds. The fact that these compounds affect

> only a portion of a cell's inflammatory response mechanism may

> explain why they do not have side effects like corticosteroids

> and other immunosuppressive drugs. Enough inflammatory genes are

> dependent on the p38/AP-1 pathway, however, that inflammation in

> tissue cannot be sustained if these genes are returned to normal

> levels of expression. The inflammation winds down over several

> days, much like a slow leak in a tire. "

>

> Since the study was conducted by the company selling the product,

> I wouldn't be surprised if it was partially biased.

> Unfortunately, even though I believe they were originally going

> to attempt to seek FDA approval for this item, it has since been

> classified as a cosmetic, and therefore not under the regulation

> of the FDA or something like that.. Not entirely sure. Anyway,

> even with this being said, this product looks to be about as

> promising as anything out there, so, you may wanna give it a try,

> especially if you have a combination of cea and Seb Derm.

>

> Sorry for makin' this so long! (I never can seem to say what I'm

> trying to say without blathering on for ten pages)

>

> Adam

>

May 22, 2002